Efficacy and safety of repaglinide, Glurenorm [gliquidone] and Glucobay [acarbose] in Chinese subjects with type 2 diabetes mellitus

Trial Profile

Efficacy and safety of repaglinide, Glurenorm [gliquidone] and Glucobay [acarbose] in Chinese subjects with type 2 diabetes mellitus

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Feb 2017

At a glance

  • Drugs Acarbose; Gliquidone; Repaglinide
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 May 2009 Actual patient number (131) added as reported by ClinicalTrials.gov.
    • 06 May 2009 Actual end date (Sep 2004) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top